通过差异解释分析通过神经网络解码心力衰竭亚型.
Mariano Ruz Jurado1,2,3, David Rodriguez Morales1,2,3, Elijah Genetzakis1,4
1Institute of Cardiovascular Regeneration, Theodor-Stern-Kai 7, Goethe University Frankfurt, Frankfurt am Main 60590, Hessen, Germany.
Briefings in bioinformatics
|November 12, 2025
概括
这项研究引入了一种新的方法,即差异解释基因 (DXGs),用于分析心力衰竭 (HF) 研究的复杂单细胞数据. DXG 提高了在不同 HF 类型中特定分子通路的识别.
科学领域:
- 基因组学就是基因组学.
- 计算生物学 计算生物学
- 心血管研究研究心血管研究
背景情况:
- 单细胞转录组学对于理解心力衰竭 (HF) 机制至关重要.
- 分析复杂的单细胞数据以找到高频类型之间的差异基因特征是具有挑战性的.
- 机器学习,特别是深度神经网络 (NN),有助于分析转录模式,但往往缺乏可解释性.
研究的目的:
- 开发一种新的方法来识别心力衰竭亚型中差异调节的基因.
- 提高单细胞转录组学中机器学习模型的可解释性.
- 使用可解释的人工智能来发现高频子类型特定的分子通路.
主要方法:
- 开发了一种新的方法来识别差异解释基因 (DXGs).
- 使用来自定制构建的深度神经网络 (NN) 的重要性得分.
- 应用可解释AI (XAI) 技术来解释NN决策.
主要成果:
- DXG成功地确定了HF亚型的特定途径.
- 与现有的工具相比,该方法在精确确定不同调节的基因方面表现出优越性.
- 揭示了对不同类型心力衰竭分子机制的新见解.
结论:
- 在心力衰竭研究中,DXG提供了一种强大的方法来分析复杂的单细胞转录组数据.
- 这种方法为未来的高频研究和治疗探索提供了基础.
- 提高机器学习模型的可解释性可以加速心血管疾病的发现.
相关概念视频
Heart Failure IV: Classification and Diagnostic Evaluation
281
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
281
Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
Heart Failure Drugs: β-Blockers
724
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
724
Heart Failure I: Introduction
653
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
653
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
